CERES, a retrospective study of patients with advanced renal cell carcinoma who received cabozantinib as part of the UK Managed Access Program: Baseline characteristics and clinical outcomes

• B. Szabados,
• A. Michael,
• T. Powles,
• K. Fife,
• B. Klair,
• V. Perrot,
• B. Venugopal

Affiliations

B. Szabados

A. Michael

T. Powles

K. Fife

B. Klair

V. Perrot

B. Venugopal